Hydroxychloroquine Market 2024-2032: Size, Share, Growth, Trends and Forecast

IMARC Group, a leading market research company, has recently releases report titled “Hydroxychloroquine Market Report by Dosage Type (200 Mg, 300 Mg, 400 Mg, and Others), Distribution (Hospital Pharmacies, Retail Pharmacies, and Others), Application (Rheumatoid Arthritis, Lupus Erythematosus, Malaria, Coronavirus (COVID-19), and Others), Grade (USP Standards Grade, EP Standards Grade, Pharmaceutical Standards Grade, and Others), Route of Administration (Oral, Intravenous), and Region 2024-2032.” The study provides a detailed analysis of the industry, including the global hydroxychloroquine market size, share, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights

How big is the hydroxychloroquine market?

The global hydroxychloroquine market size reached US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.98% during 2024-2032.

What is hydroxychloroquine?

Hydroxychloroquine is a medication that belongs to a class of drugs called antimalarials. It is primarily used for the prevention and treatment of malaria, a parasitic infection transmitted by mosquitoes. It is derived from the closely related drug chloroquine but has been developed to have a better safety profile and improved tolerability. In addition to its antimalarial properties, hydroxychloroquine possesses immunomodulatory effects. It is commonly prescribed for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis and systemic lupus erythematosus (SLE). By suppressing the activity of the immune system, hydroxychloroquine helps alleviate the symptoms of these conditions, including joint pain, inflammation, and fatigue. The manufacturing process for hydroxychloroquine involves several steps. The resulting hydroxychloroquine is then purified through processes such as filtration, crystallization, and drying to obtain the final product in the desired form, typically as a powder or solid. Moreover, quality control measures, including testing for purity and potency, are carried out throughout the manufacturing process to ensure the safety and efficacy of the finished hydroxychloroquine product.

Request for a sample copy of this report: https://www.imarcgroup.com/hydroxychloroquine-market/requestsample

What are the growth prospects and trends in the hydroxychloroquine industry?

One of the primary factors driving the market is the rising product adoption in the treatment for malaria. Hydroxychloroquine's effectiveness in preventing and treating malaria infections has made it a widely prescribed medication in regions where malaria is prevalent. Additionally, hydroxychloroquine has been a crucial therapeutic option for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE), representing another major growth-inducing factor. Besides, the rising prevalence of these conditions, coupled with the need for effective disease-modifying drugs, has contributed to the demand for hydroxychloroquine. Moreover, the affordability and availability of hydroxychloroquine have also played a role in its market growth. It is a relatively inexpensive medication, making it accessible to patients in low-income regions and contributing to its widespread use. Additionally, the rising product adoption in reducing pain, swelling, and joint stiffness among individuals is also propelling the market growth. Apart from this, the market is also propelled by the rising utilization of hydroxychloroquine to treat porphyria cutanea tarda, a disorder wherein an individual suffer from a painful and blistering skin due to sensitivity to sunlight. Furthermore, the developing healthcare infrastructure across the globe, and the wide availability of these medicines through online and offline pharmacy stores, the increasing research and development (R&D) activities conducted for possible uses, and mergers and acquisitions (M&As) and partnerships among the leading players are other factors creating a favorable market outlook.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Dosage Type:

• 200 Mg
• 300 Mg
• 400 Mg
• Others

Breakup by Distribution:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Breakup by Application:

• Rheumatoid Arthritis
• Lupus Erythematosus
• Malaria
• Coronavirus (COVID-19)
• Others

Breakup by Grade:

• USP Standards Grade
• EP Standards Grade
• Pharmaceutical Standards Grade
• Others

Breakup by Route of Administration:

• Oral
• Intravenous

Breakup by Region:

• North America (U.S. & Canada)
• Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
• Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
• Latin America (Brazil, Mexico)
• Middle East & Africa

Who are the key players operating in the industry?

The report covers the major market players including:

• Amneal Pharmaceuticals Inc.
• Cipla Ltd.
• Ipca Laboratories Ltd.
• Laurus Labs
• Lupin Limited
• Mylan N.V.
• Prasco Laboratories
• Reddy’s Laboratories Ltd.
• Sanofi S.A.
• Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.),
• Torrent Pharmaceuticals Ltd.
• Zydus Lifesciences Limited

Ask Analyst and Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=2266&flag=C

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Browse More Latest Reports:

Asia Pacific Dental Implants Market Size

Europe Natural Sweetener Market Size

India Pub, Bar, Café and Lounge (PBCL) Market Size

GCC Personal Luxury Goods Market Size

Europe Ceiling Fan Market Size

Green Coatings Market Size

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: sales@imarcgroup.com

Follow us on Twitter: @imarcglobal